Magnitude of clinical responses with izokibep in psoriatic arthritis continues to improve

12 April 2023

Privately-held US clinical-stage immunology specialist Acelyrin has announced long-term 46-week data from a global Phase II trial of izokibep in psoriatic arthritis (PsA).

Izokibep is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody.

Just last month, Acelyrin announced data from the open label Part A of a Phase IIb/III trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) that demonstrated treatment with its lead candidate izokibep resulted high orders (HiSCR75 and above) of HiSCR response at 12 weeks, including HiSCR100 responses in 33% of participants, claiming these results are better than any seen before.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK